tbuckley/cabot-search huggingface dataset:
Intracranial Hypertension and Minocycline
Authors: Joseph Shiri
Journal: Annals of Internal Medicine (1997)

Letters15 July 1997Intracranial Hypertension and MinocyclineJoseph Shiri, MD and Boaz Amichai, MDJoseph Shiri, MDTel-Nordoy Clinic; Tel-Aviv, Israel and Boaz Amichai, MDTel-Nordoy Clinic; Tel-Aviv, IsraelAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-127-2-199707150-00030 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We report a case of intracranial hypertension with permanent visual damage after minocycline treatment.A 19-year-old healthy woman was treated with minocycline, 100 mg/d, for acne vulgaris. Two weeks after treatment began, the patient presented with severe headache, nausea, and visual disturbance. Ophthalmologic examination revealed severe bilateral papilledema with visual field damage. A computed tomographic scan of the brain was normal. After minocycline therapy was discontinued and acetazolamide was administered, the papilledema disappeared. However, the patient's visual fields and visual acuity are permanently damaged.Tetracyclines, especially minocycline, are widely used to treat acne vulgaris. Despite the listed ...References1. Lubetzki C, Sanson M, Cohen D, et al. Benign intracranial hypertension and minocycline. Rev Neurol Paris. 1988; 144:218-20. Google Scholar2. Delaney RA, Narayanswamy TR, Wee D. Pscudo-tumor cerebri and acne. Mil Med. 1990:155:511. Google Scholar3. Le-Bris P, Glacet-Breard A, Coscas G, et al. Papilledema caused by minocycline: apropos of a case. J Fr Ophthalmol. 1988:11:681-4. Google Scholar4. Lander CM. Minocycline-induced benign intracranial hypertension. Clin Exp Neurol. 1989; 26:161-7. Google Scholar5. Donnet A, Dufour H, Graziani N, et al. Minocycline and benign intracranial hypertension. Biomed Pharmacother. 1992; 46:171-2. Google Scholar Author, Article, and Disclosure InformationAffiliations: Tel-Nordoy Clinic; Tel-Aviv, Israel PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByDapsone, penicillamine, thalidomide, bucillamine, and the tetracyclinesSide Effects of Minocycline Treatment in Patients With Fragile X Syndrome and Exploration of Outcome MeasuresWhat is New About Idiopathic Intracranial Hypertension? An Updated Review of Mechanism and TreatmentSafety of doxycycline and minocycline: A systematic reviewCyclines et acné : attention aux effets indésirables ! Aspects récents de la littératureTetracyclines for the treatment of rheumatoid arthritisComplications of Minocycline Therapy for Acne Vulgaris: Case Reports and Review of the LiteraturePenicillins, cephalosporins, other β-lactam antibiotics, and tetracyclinesMINOCYCLINE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS 15 July 1997Volume 127, Issue 2Page: 168KeywordsAcneHeadachesHypertensionInfantsNauseaPatientsRetinoidsSigns and symptomsTetracyclinesVisual acuity Issue Published: 15 July 1997 CopyrightCopyright © 1997 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Mechanism of action of lenalidomide in hematological malignancies
Authors: Venumadhav Kotla, Swati Goel, Sangeeta Nischal, Christoph Heuck, Kumar Vivek, Bhaskar Das, Amit Verma
Journal: Journal of Hematology & Oncology (2009)

Abstract Immunomodulatory drugs lenalidomide and pomalidomide are synthetic compounds derived by modifying the chemical structure of thalidomide to improve its potency and reduce its side effects. Lenalidomide is a 4-amino-glutamyl analogue of thalidomide that lacks the neurologic side effects of sedation and neuropathy and has emerged as a drug with activity against various hematological and solid malignancies. It is approved by FDA for clinical use in myelodysplastic syndromes with deletion of chromosome 5q and multiple myeloma. Lenalidomide has been shown to be an immunomodulator, affecting both cellular and humoral limbs of the immune system. It has also been shown to have anti-angiogenic properties. Newer studies demonstrate its effects on signal transduction that can partly explain its selective efficacy in subsets of MDS. Even though the exact molecular targets of lenalidomide are not well known, its activity across a spectrum of neoplastic conditions highlights the possibility of multiple target sites of action.
LOCAL EFFECT OF COMPOUND F ON REACTIONS TO MOSQUITO BITES
Authors: Leon Goldman
Journal: JAMA (1952)

Studies on the local effect of the oxysteroids have been under way in the department of dermatology and syphilology for some time. Previous studies<sup>1</sup>with local application and local injection of cortisone acetate and a water soluble ester of cortisone had produced no constant positive results in a large series of clinical cases nor did the detailed animal experiments of Nilzen.<sup>2</sup>This is contrary, of course, to the brilliant results obtained locally in diseases of the eye. Preliminary studies,<sup>3</sup>however, with compound F have already revealed significant evidences of a local effect. Gibson<sup>4</sup>has indicated that compound F has more local activity than cortisone. The following case is reported in order to show the definite and prolonged inhibitory local effect of compound F on severe reactions to mosquito bites. <h3>REPORT OF CASE</h3> The patient was a 46-year-old physician with a history of reaction to bites of
Staging of Lymphoma: Clinical, Radiographic, Scintigraphic, and Histologic Correlations.
Authors: Edgar M. Moran
Journal: Annals of Internal Medicine (1973)

Meeting Abstracts1 May 1973Staging of Lymphoma: Clinical, Radiographic, Scintigraphic, and Histologic Correlations.Edgar M. Moran, M.D., Paul B. Hoffer, M.D., Donald J. Ferguson, M.D., Klaus Ranniger, M.D., Henry Rappaport, M.D., F.A.C.P., John E. Ultmann, M.D., F.A.C.P.Edgar M. Moran, M.D.Search for more papers by this author, Paul B. Hoffer, M.D.Search for more papers by this author, Donald J. Ferguson, M.D.Search for more papers by this author, Klaus Ranniger, M.D.Search for more papers by this author, Henry Rappaport, M.D., F.A.C.P.Search for more papers by this author, John E. Ultmann, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-78-5-824_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe usefulness of staging laparotomy has gained acceptance in the evaluation of Hodgkin's disease. We report our results in the staging of other lymphomas. Fifty-seven patients (26 males, 31 females; ages 14 to 68 years) with poorly differentiated lymphocytic (24 cases), mixed cell (8 cases), and histiocytic (25 cases) lymphoma were studied. None of these patients had established stage IV disease. Their evaluation included a physical examination, chest X ray, skeletal survey, intravenous pyelogram, inferior venacavagram, bipedal lymphangiogram (LAF), technetium-99m liver, spleen, and bone marrow scans, gallium-67 scan, liver function tests, and bone marrow examination. Staging laparotomy included a splenectomy;... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Chicago, Illinois PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byMycosis fungoides: Pathologic findings in staging laparotomiesMorphological studies of 84 untreated patients subjected to laparotomy for the staging of non-Hodgkin's lymphomas 1 May 1973Volume 78, Issue 5Page: 824-824KeywordsBone marrowHodgkin lymphomaIntravenous pyelographyLaparotomyLiverLiver function testsLymphomaSpleenSplenectomyThorax Issue Published: 1 May 1973 PDF downloadLoading ...
Multiplex, Quantitative, Real-time PCR Is A Sensitive, Inexpensive And Rapid Assay To Detect Digeorge Syndrome (DGS1) And Can Be Adapted To Newborn Screening
Authors: A.T. Mitchell, D. Mahnke, D. Mickle, P. Simpson, W. Grossman, K. Sullivan, B.S. Emanuel, J.S. Tweddell, M.E. Mitchell, M.W. Baker, J.M. Routes
Journal: Journal of Allergy and Clinical Immunology (2010)
Novel MT1-MMP Small-Molecule Inhibitors Based on Insights into Hemopexin Domain Function in Tumor Growth
Authors: Albert G. Remacle, Vladislav S. Golubkov, Sergey A. Shiryaev, Russell Dahl, John L. Stebbins, Andrei V. Chernov, Anton V. Cheltsov, Maurizio Pellecchia, Alex Y. Strongin
Journal: Cancer Research (2012)

Membrane type-1 matrix metalloproteinase (MT1-MMP) is a promising drug target in malignancy. The structure of MT1-MMP includes the hemopexin domain (PEX) that is distinct from and additional to the catalytic domain. Current MMP inhibitors target the conserved active site in the catalytic domain and, as a result, repress the proteolytic activity of multiple MMPs instead of MT1-MMP alone. In our search for noncatalytic inhibitors of MT1-MMP, we compared the protumorigenic activity of wild-type MT1-MMP with an MT1-MMP mutant lacking PEX (ΔPEX). In contrast to MT1-MMP, ΔPEX did not support tumor growth in vivo, and its expression resulted in small fibrotic tumors that contained increased levels of collagen. Because these findings suggested an important role for PEX in tumor growth, we carried out an inhibitor screen to identify small molecules targeting the PEX domain of MT1-MMP. Using the Developmental Therapeutics Program (National Cancer Institute/NIH), virtual ligand screening compound library as a source and the X-ray crystal structure of PEX as a target, we identified and validated a novel PEX inhibitor. Low dosage, intratumoral injections of PEX inhibitor repressed tumor growth and caused a fibrotic, ΔPEX-like tumor phenotype in vivo. Together, our findings provide a preclinical proof of principle rationale for the development of novel and selective MT1-MMP inhibitors that specifically target the PEX domain.
Oral tolerance in the absence of naturally occurring Tregs
Authors: D. Mucida
Journal: Journal of Clinical Investigation (2005)

Mucosal tolerance prevents pathological reactions against environmental and food antigens, and its failure results in exacerbated inflammation typical of allergies and asthma. One of the proposed mechanisms of oral tolerance is the induction of Tregs. Using a mouse model of hyper-IgE and asthma, we found that oral tolerance could be effectively induced in the absence of naturally occurring thymus-derived Tregs. Oral antigen administration prior to i.p. immunization prevented effector/memory Th2 cell development, germinal center formation, class switching to IgE, and lung inflammation. Oral exposure to antigen induced development of antigen-specific CD4CD25Foxp3CD45RB cells that were anergic and displayed suppressive activity in vivo and in vitro. Oral tolerance to the Th2 allergic response was in large part dependent on TGF-beta and independent of IL-10. Interestingly, Tregs were also induced by single i.p. immunization with antigen and adjuvant. However, unlike oral administration of antigen, which induced Tregs but not effector T cells, i.p. immunization led to the simultaneous induction of Tregs and effector Th2 cells displaying the same antigen specificity.
Abstract 4975: Identification of a novel interaction between EZH2 and p38 in triple negative breast cancer
Authors: Talha Anwar, Heather Moore, Maria E. Gonzalez, Celina Kleer
Journal: Cancer Research (2014)

Abstract Background: Breast cancer accounts for more than 40,000 deaths yearly in the United States, the majority of which are due to metastatic disease. The histone methyltransferase EZH2 (Enhancer of Zeste Homolog 2) is a member of the polycomb repressive complex 2 (PRC2) responsible for transcriptional repression by trimethylation of histone H3 at lysine 27. EZH2 is an independent predictor of recurrence and mortality that is overexpressed in 55% of invasive breast carcinomas. We previously identified a novel link between EZH2 and the p38 mitogen-activated protein kinase, an important mediator of breast cancer progression and metastasis. EZH2 binds to p38, and overexpression of EZH2 leads to phosphorylation and activation of p38. Based on in vitro evidence and recent studies implicating EZH2 in the methylation of non-histone targets, we hypothesized that EZH2 may methylate p38 in breast cancer cells. We further hypothesized that this methylation event may be important for p38 activation or stability. Methods: In order to test this hypothesis, we used stable shRNA knockdown of EZH2 in MDA-MB-231 and SUM149 breast cancer cell lines. We performed co-immunoprecipitation using p38 and pan-methyl lysine antibodies to assess changes in methylated p38 by immunoblot. We are currently performing LC MS/MS analysis to identify the specific residues that are methylated by PRC2 both in vitro and in vivo. Additionally, in order to localize this interaction, we performed co-immunoprecipitation experiments on fractionated MDA-MB-231 and SUM149 lysates. Results: Stable knockdown of EZH2 resulted in reduced methylated p38 compared to vector controls, suggesting that EZH2 methylates p38 in vivo. We found that EZH2 and p38 interact in nuclear and, surprisingly, cytoplasmic fractions. Conclusions. We provide evidence that in addition to being a nuclear protein, EZH2 can be found in the cytoplasm of TNBCs, where it is able to complex with p38. Taken together, our data suggest that p38 methylation may represent an additional mechanism by which EZH2 mediates breast cancer progression in TNBC. Citation Format: Talha Anwar, Heather Moore, Maria E. Gonzalez, Celina Kleer. Identification of a novel interaction between EZH2 and p38 in triple negative breast cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4975. doi:10.1158/1538-7445.AM2014-4975
Treatment of Acute Rheumatism with Butazolidin
Authors: J. Fleming, G. Will
Journal: Annals of the Rheumatic Diseases (1953)

A favourable experience of Butazolidin in the treatment of rheumatoid arthritis and the experi- mental reports that it appears to influence the resolution of inflammatory exudates, suggested that it might be of use in treating acute rheumatism.Case Reports (1) Female, aged 17, had been treated for rheumatic fever 3 years ago, but it appeared to have been a mild attack, and she had been well since; 6 days before admission she had developed pain, stiffness, and swelling of both ankles, and the knees, hands, and shoulders also became involved; 3 days later she had sternal and inter- scapular pain with cough, and complained also of anorexia, headache, profuse perspiration, and occasional vomiting.The joint pains responded to some extent to salicylate.Examination.-Onadmission (temperature 101.20 F., pulse 110, respirations 25), she complained of severe sternal pain and was dyspnoeic and cyanosed.There was no notable swelling of the joints, but the knees were 'o, on July 27, 2023 by guest.
NHS cuts will make up a third of 11bn savings across public services
Authors: Z. Kmietowicz
Journal: BMJ (2010)

The health sector is to contribute the most out of the pubic services towards repaying the country’s debt by making £4.35bn (€4.83bn; $6.5bn) worth of efficiency savings by 2012-13, the government announced in the budget this week.

The Chancellor Alistair Darling confirmed it will stick to its plans to keep NHS spending at its current level in 2010-2011, but that from 2011 it would be seeking annual savings of £11bn across government departments to halve public spending as a proportion of the economy over the next four years.

Health Secretary Andy Burnham said the NHS savings would be made by cutting £1.5bn from the costs of procurement, £100m from the National Programme for IT, £130m by reducing energy consumption and managing estates more efficiently, and up to £555m by reducing staff sick absence.

Mr Burnham, …
Rapid mobilization of murine hematopoietic stem cells with enhanced engraftment properties and evaluation of hematopoietic progenitor cell mobilization in rhesus monkeys by a single injection of SB-251353, a specific truncated form of the human CXC chemokine GROβ
Authors: Andrew G. King, Dan Horowitz, Susan B. Dillon, Robert Levin, Ann M. Farese, Thomas J. MacVittie, Louis M. Pelus
Journal: Blood (2001)
Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy
Authors: Carlo Minetti, Federica Sotgia, Claudio Bruno, Paolo Scartezzini, Paolo Broda, Massimo Bado, Emiliana Masetti, Michela Mazzocco, Aliana Egeo, Maria Alice Donati, Daniela Volonté, Ferruccio Galbiati, Giuseppe Cordone, Franca Dagna Bricarelli, Michael P. Lisanti, Federico Zara
Journal: Nature Genetics (1998)
Prostate Cancer: Emerging Concepts
Authors: Timothy J. Wilt
Journal: Annals of Internal Medicine (1996)

Letters15 December 1996Prostate Cancer: Emerging ConceptsTimothy J. Wilt, MD, MPHTimothy J. Wilt, MD, MPHMinneapolis Veterans Affairs Medical Center, Minneapolis, MN 55417.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-125-12-199612150-00033 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The Update by Garnick and Fair [1] selectively emphasizes data from uncontrolled reports to suggest that screening and aggressive treatment of prostate cancer are beneficial, but it ignores or dismisses the preponderance of evidence showing that early detection and intervention are not of proven benefit. The American Urological Association Treatment Guidelines Panel [2] and the U.S. Preventive Services Task Force [3] have published evidence-based reviews on early prostate cancer detection and treatment that do not support the strategies advocated by Garnick and Fair.The American Urological Association Panel found the data to be inadequate for valid comparisons ...References1. Garnick MB, Fair WR. Prostate cancer: emerging concepts. Part I. Ann Intern Med. 1996; 125:118-25. Google Scholar2. Middleton RG, Thompson IM, Austenfeld MS, Cooner WH, Correa RJ, Gibbons RP. Prostate cancer clinical guidelines panel summary report on the management of clinically localized prostate cancer. J Urol. 1995; 154:2144-8. Google Scholar3. Screening for prostate cancer. In: U.S. Preventive Services Task Force. Guide to Clinical Preventive Services. 2d ed. Baltimore: Williams & Wilkins; 1996:119-34. Google Scholar4. Cantor SB, Spann SJ, Volk RJ, Cardenas MP, Warren MM. Prostate cancer screening: a decision analysis. J Fam Pract. 1995; 41:33-41. Google Scholar5. Barry MJ, Fleming C, Coley CM, Wasson JH, Fahs MC, Oesterling JE. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV: Estimating the risks and benefits of an early detection program. Urology. 1995; 46:445-61. Google Scholar Author, Article, and Disclosure InformationAffiliations: Minneapolis Veterans Affairs Medical Center, Minneapolis, MN 55417. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 December 1996Volume 125, Issue 12Page: 1014-1015KeywordsAntigensCancer screeningCancer treatmentProstate cancerQuality of lifeRadiation therapyRadical prostatectomyRandomized trialsResearch designTreatment guidelines Issue Published: 15 December 1996 CopyrightCopyright © 1996 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
The epidemiology of breast cancer
Authors: J. L. Kelsey, M. D. Gammon
Journal: CA A Cancer Journal for Clinicians (1991)

Table 5 presents risk factors for breast cancer generally regarded as established, together with their approximate relative risks. With the exception of age, country of birth, and a history of breast cancer in both a mother and a sister, all of the relative risks reported to date are of a relatively modest magnitude. Thus, new risk factors need to be identified and knowledge of existing risk factors refined. Factors for which the evidence of an etiologic role has mounted over the past several years, but which are not yet considered to be established, include the protective effects of parity and lactation in certain age groups and the increased risks associated with alcohol consumption and with DES exposure during pregnancy. In addition, physical activity has emerged as a factor worthy of further study. Some evidence suggests that use of oral contraceptives for several years at an early age modestly increases the risk for breast cancer diagnosed before age 35 and perhaps age 45. Use of estrogen-replacement therapy for 20 years or more has been found by a few studies to increase the risk for breast cancer in the postmenopausal years; further studies of very long-term users are needed. Also, other risks and benefits of these hormones need to be taken into account when women decide whether to use them. Surprisingly elusive has been the etiologic role of endogenous hormones, especially in view of the large number of studies that have been concerned with them. A better understanding of the role of endogenous hormones should help explain the mechanisms of action of known and suspected risk factors. Areas of high priority for further research thus include establishing with more certainty whether the risk for breast cancer is increased in any subgroups of women who use oral contraceptives and estrogen-replacement therapy and determining the etiologic roles of specific endogenous hormones. The possible risks associated with alcohol consumption and lack of physical activity need to be studied more thoroughly, and ideas about new potential risk factors are needed. Although epidemiologic studies will continue to be concerned with diet, enthusiasm for its etiologic role in women has been considerably dampened by the lack of association in many of the studies reported to date. The studies in women exposed to radiation, DES, and oral contraceptives suggest that the timing of some exposures may be critical, since the effects of these agents may mostly be limited to specific time periods of rapid breast development.(ABSTRACT TRUNCATED AT 400 WORDS)